Encorafenib/Binimetinib for BRAF V600-Mutant Melanoma With Paolo Ascierto, MD

Combination BRAF/MEK inhibitors such as encorafenib/binimetinib are the current standard of care for patients with BRAF V600-mutant melanoma. Until now, however, the long-term efficacy of encorafenib/binimetinib had not been established. In an updated analysis of the phase 3 COLUMBUS trial, a team of researchers led by Paolo Ascierto, MD, Director of the Unit of Melanoma, Cancer Immunotherapy, and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, Italy, found th...
Continue reading

Alcohol Use in Cancer Survivors With Nina Sanford, MD

Alcohol use, particularly at high levels, is known to be both a risk factor for cancer and a contributor to poor oncologic outcomes. However, few guidelines are in place for health care providers to counsel their patients regarding alcohol consumption both during and after treatment. In a study now published in the Journal of the National Comprehensive Cancer Network, a team of researchers led by Nina Sanford, MD, Assistant Professor of Radiation Oncology at the University of Texas Southwestern ...
Continue reading

Insurance Status Contributes to Racial Disparities in Breast Cancer

A new study reports that a lack of adequate health insurance is responsible for nearly half of racial and ethnic disparities in breast cancer stage at diagnosis.Earlier detection and treatment of breast cancer can significantly improve outcomes for patients diagnosed with this disease. However, studies have shown that a higher proportion of women of racial and ethnic minorities present with breast cancer at more advanced stages, negatively impacting their treatment and prognosis. In a study now ...
Continue reading

Enfortumab Vedotin for Advanced Urothelial Carcinoma With Peter H. O'Donnell, MD

The FDA recently approved enfortumab vedotin (Padcev®, Astellas Pharma US, Inc.) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed after treatment with platinum-based chemotherapy and anti–programmed cell death protein 1 (anti–PD-1) or anti–programmed death ligand 1 (anti–PD-L1) therapy. The approval was based on EV-201, a phase 2 trial in which enfortumab vedotin produced a high rate of response in patients with locally advanced or m...
Continue reading

Pembrolizumab Approval: Non-Muscle Invasive Bladder Cancer

The FDA has approved pembrolizumab (Keytruda®, Merck) for the treatment of patients with high-risk non-muscle invasive bladder cancer (NMIBC) carcinoma in situ, with or without papillary tumors. Pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, is indicated for patients who are ineligible for or have elected not to receive radical cystectomy and who do not respond to bacillus Calmette-Guérin (BCG) therapy.The approval was based on Keynote 057 (NCT02625961), a multicenter, single...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.